A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Condition: Cervical Cancer Interventions: Drug: TQB2868 injection; Drug: Paclitaxel injection; Drug: Cisplatin injection; Drug: Carboplatin injection; Drug: Bevacizumab injection Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
Condition: Colorectal Cancer Interventions: Drug: all trans Retinoic Acid; Drug: Atezolizumab; Drug: Bevacizumab Sponsors: University of Texas Southwestern Medical Center; Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
Conditions: Hepatocellular Carcinoma; Hepatocellular Cancer; Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Stage IV; Liver Cancer Interventions: Radiation: Atezolizumab plus bevacizumab, combined EBRT to vascular invasion; Drug: Atezolizumab plus bevacizumab Sponsors: Asan Medical Center; Seoul National University Hospital; Hanyang University; Soon Chun Hyang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
